nach oben

Erschienen in:

01.10.2014 | Review article

Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma

When should they be considered and which questions remain open?

verfasst von: Frank Lohr, M.D., Dietmar Georg, Ph.D., Luca Cozzi, Ph.D., Hans Theodor Eich, M.D., Damien C. Weber, M.D., Julia Koeck, M.D., Barbara Knäusl, Ph.D., Karin Dieckmann, Yasser Abo-Madyan, M.D., Christian Fiandra, Rolf-Peter Mueller, M.D., Andreas Engert, M.D., Umberto Ricardi, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hodgkin lymphoma (HL) is a highly curable disease. Reducing late complications and second malignancies has become increasingly important. Radiotherapy target paradigms are currently changing and radiotherapy techniques are evolving rapidly.

Design

This overview reports to what extent target volume reduction in involved-node (IN) and advanced radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT) and proton therapy–compared with involved-field (IF) and 3D radiotherapy (3D-RT)– can reduce high doses to organs at risk (OAR) and examines the issues that still remain open.

Results

Although no comparison of all available techniques on identical patient datasets exists, clear patterns emerge. Advanced dose-calculation algorithms (e.g., convolution-superposition/Monte Carlo) should be used in mediastinal HL. INRT consistently reduces treated volumes when compared with IFRT with the exact amount depending on the INRT definition. The number of patients that might significantly benefit from highly conformal techniques such as IMRT over 3D-RT regarding high-dose exposure to organs at risk (OAR) is smaller with INRT. The impact of larger volumes treated with low doses in advanced techniques is unclear. The type of IMRT used (static/rotational) is of minor importance. All advanced photon techniques result in similar potential benefits and disadvantages, therefore only the degree-of-modulation should be chosen based on individual treatment goals. Treatment in deep inspiration breath hold is being evaluated. Protons theoretically provide both excellent high-dose conformality and reduced integral dose.

Conclusion

Further reduction of treated volumes most effectively reduces OAR dose, most likely without disadvantages if the excellent control rates achieved currently are maintained. For both IFRT and INRT, the benefits of advanced radiotherapy techniques depend on the individual patient/target geometry. Their use should therefore be decided case by case with comparative treatment planning.

Andolino DL, Hoene T, Xiao L et al (2011) Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys 81:e667–e671

Behringer K, Josting A, Schiller P et al (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15:1079–1085PubMedCrossRef

Berrington de Gonzalez A, Gilbert E, Curtis R et al (2013) Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 86:224–233PubMedCrossRef

Bert C, Richter D, Durante M et al (2012) Scanned carbon beam irradiation of moving films: comparison of measured and calculated response. Radiat Oncol 7:55PubMedCrossRefPubMedCentral

Brodin NP, Maraldo MV, Aznar MC et al (2014) Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 88:433–445PubMedCrossRef

Campbell BA, Hornby C, Cunninghame J et al (2012) Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23:1259–1266PubMedCrossRef

Campbell BA, Voss N, Pickles T et al (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174PubMedCrossRef

Cella L, Conson M, Pressello MC et al (2013) Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol 8:22PubMedCrossRefPubMedCentral

Chera BS, Rodriguez C, Morris CG et al (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173–1180PubMedCrossRef

10.

Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998PubMedCrossRef

11.

De Bruin ML, Sparidans J, van’t Veer MB et al (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246

12.

De Sanctis V, Bolzan C, D’Arienzo M et al (2012) Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol 7:129PubMedCrossRefPubMedCentral

13.

Dorr W, Herrmann T (2008) Second tumors after oncologic treatment. Strahlenther Onkol 184:67–72PubMedCrossRef

14.

Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206PubMedCrossRef

15.

Eich HT, Kriz J, Muller RP (2011) Evolution of radiation therapy within the German Hodgkin Study Group trials. J Natl Compr Canc Netw 9:1073–1080PubMed

16.

Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410PubMedCrossRef

17.

Fiandra C, Filippi A, Catuzzo P et al (2012) Different IMRT solutions vs. 3D-Conformal Radiotherapy in Early Stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186PubMedCrossRefPubMedCentral

18.

Filippi AR, Ragona R, Fusella M et al (2013) Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Radiation Oncology 3:216–222PubMedCrossRef

19.

Franklin J, Pluetschow A, Paus M et al (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17:1749–1760PubMedCrossRef

20.

Gagliardi G, Constine LS, Moiseenko V et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85CrossRef

21.

Girinsky T, Pichenot C, Beaudre A et al (2006) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218–226PubMedCrossRef

22.

Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210PubMedCrossRef

23.

Glanzmann C, Veraguth A, Lutolf UM (1994) Incidence of second solid cancer in patients after treatment of Hodgkin’s disease. Strahlenther Onkol 170:140–146PubMed

24.

Hall EJ (2006) Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65:1–7PubMedCrossRef

25.

Hodgson DC, Koh ES, Tran TH et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586PubMedCrossRef

26.

Hoppe BS, Flampouri S, Su Z et al (2012) Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 84:449–455PubMedCrossRef

27.

Hoppe BS, Flampouri S, Su Z et al (2011) Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys 83:260–267PubMedCrossRef

28.

Jang SY, Liu HH, Mohan R (2008) Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 71:1537–1546PubMedCrossRef

29.

Keilholz L, Willner J, Thiel HJ et al (2014) Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial. Strahlenther Onkol 190:17–25PubMedCrossRef

30.

Knäusl B, Lütgendorf-Caucig C, Hopfgartner J et al (2013) Can treatment of Paediatric Hodgkin’s Lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol 189:54–61PubMedCrossRef

31.

Koeck J, Abo-Madyan Y, Eich HT et al (2012) Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin’s disease. Strahlenther Onkol 188:653–659PubMedCrossRef

32.

Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys; 83:268–276PubMedCrossRef

33.

Koelbl O, Krieger T, Haedinger U et al (2004) Influence of calculation algorithm on dose distribution in irradiation of non-small cell lung cancer (NSCLC) collapsed cone versus pencil beam. Strahlenther Onkol 180:783–788PubMedCrossRef

34.

Li J, Dabaja B, Reed V et al (2011) Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 81:167–174PubMedCrossRef

35.

Lohr F, El-Haddad M, Dobler B et al (2009) Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. Int J Radiat Oncol Biol Phys 74:73–80PubMedCrossRef

36.

Lütgendorf-Caucig C, Fotina I Gallop-Evans E, et al (2013) Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin’s lymphoma. A case study. Strahlenther Onkol 188:1025–1030CrossRef

37.

Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399–408PubMedCrossRefPubMedCentral

38.

Moskowitz CS, Chou JF, Wolden SL et al (2012) New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: a report from the Childhood Cancer Survivor Study (CCSS) and the Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study. J Clin Oncol 30

39.

Newhauser WD, Durante M (2011) Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 11:438–448PubMedCrossRefPubMedCentral

40.

Nieder C, Schill S, Kneschaurek P et al (2007) Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2:20PubMedCrossRefPubMedCentral

41.

Nilsson G, Holmberg L, Garmo H et al (2012) Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380–386PubMedCrossRef

42.

Paganetti H (2012) Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol 57:R99–117PubMedCrossRefPubMedCentral

43.

Paganetti H, Athar BS, Moteabbed M et al (2012) Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol 57:6047–6061PubMedCrossRef

44.

Paumier A, Ghalibafian M, Gilmore J et al (2012) Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527PubMedCrossRef

45.

Paumier A, Khodari W, Beaudre A et al (2012) Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute. Cancer Radiother 15:709–715CrossRef

46.

Pierce DA, Shimizu Y, Preston DL et al (2012) Studies of the mortality of atomic bomb survivors. report 12, part I. Cancer: 1950–1990. Radiat Res 178:AV61–87

47.

Pommier P, Dussart S, Girinsky T et al (2011) Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. Int J Radiat Oncol Biol Phys 79:823–828PubMedCrossRef

48.

Rombi B, DeLaney TF, MacDonald SM et al (2012) Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 82:1142–1148PubMedCrossRef

49.

Schneider U, Lomax A, Pemler P et al The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 182:647–652

50.

Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5PubMedCrossRef

51.

Sharma S, Ott J, Williams J et al (2011) Dose calculation accuracy of the Monte Carlo algorithm for CyberKnife compared with other commercially available dose calculation algorithms. Med Dosim 36:347–350PubMedCrossRef

52.

Slanina J, Heinemann F, Henne K et al (1999) [Second malignancies after the therapy of Hodgkin’s disease: the Freiburg collective 1940–1991]. Strahlenther Onkol 175:154–161PubMedCrossRef

53.

Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase iii trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333PubMedCrossRef

54.

Specht L, Yahalom J, Illidge T et al ( 2014) Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862

55.

Vorwerk H, Zink K, Schiller R et al (2014) Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT. Strahlenther Onkol 190:433–443PubMedCrossRef

56.

Weber DC, Johanson S, Peguret N et al (2011) Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 81:490–497PubMedCrossRef

57.

Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586PubMedCrossRef

58.

Weber DC, Trofimov AV, Delaney TF et al (2004) A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 58:1596–1606PubMedCrossRef

59.

Wolden SL, Lamborn KR, Cleary SF et al (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16:536–544PubMed

60.

Zelefsky MJ, Pei X, Teslova T et al (2012) Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 110:1696–1701PubMedCrossRef

Titel: Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma
When should they be considered and which questions remain open?
verfasst von: Frank Lohr, M.D.
Dietmar Georg, Ph.D.
Luca Cozzi, Ph.D.
Hans Theodor Eich, M.D.
Damien C. Weber, M.D.
Julia Koeck, M.D.
Barbara Knäusl, Ph.D.
Karin Dieckmann
Yasser Abo-Madyan, M.D.
Christian Fiandra
Rolf-Peter Mueller, M.D.
Andreas Engert, M.D.
Umberto Ricardi, M.D.
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0719-9

Springer Medizin

Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma

When should they be considered and which questions remain open?